ImmunoGen (IMGN) to Discontinue IMGN388 Development, Will Refocus Resources
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Down)Join SI Premium – FREE
ImmunoGen, Inc. (Nasdaq: IMGN) has decided to discontinue further development of IMGN388 to focus our resources on other, wholly owned product candidates and programs that we believe are more promising.
IMGN388 was initially developed by the Centocor (now Janssen Biotech) unit of Johnson & Johnson (NYSE: JNJ), which retained opt-in rights for the compound. Findings with IMGN388 in Phase I clinical testing include that the compound is generally well tolerated and can achieve sustained stable disease in some patients (EORTC-NCI-AACR abstract #472, Nov. 2010).
IMGN388 was initially developed by the Centocor (now Janssen Biotech) unit of Johnson & Johnson (NYSE: JNJ), which retained opt-in rights for the compound. Findings with IMGN388 in Phase I clinical testing include that the compound is generally well tolerated and can achieve sustained stable disease in some patients (EORTC-NCI-AACR abstract #472, Nov. 2010).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
- Central Securities (CET) Releases Report to Stockholders
- Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
